Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

Quadra Assura MP™ CRT-D

Quadra Assura MP CRT-D
Clinical Evidence

More Options to Make Non-Response a Non-Issue

The Quadra Assura MP™ CRT-D brings MultiPoint™ Pacing, an exclusive Abbott technology, to cardiac resynchronization therapy defibrillators (CRT-Ds).

Overview

MultiPoint Pacing technology is designed to deliver multiple independent left ventricular (LV) pacing pulses from a single quadripolar lead to provide you with CRT options to change:

  • Pattern of depolarization
  • Engagement of areas around scar tissue
  • Hemodynamics
  • Resynchronization

The Quadra Assura MP CRT-D with Quartet™ quadripolar LV pacing lead, with its four pacing electrodes and 10 pacing vectors, provides more options and greater control in CRT response.
 

U.S. IDE Study: Importance of MPP Technology Programming1

The recent IDE study1 post-hoc subanalysis (n = 199) showed that wider cathode spacing and near-simultaneous intraventricular timing delays provide best MultiPoint Pacing technology response at 87 percent and “super-response” at 54 percent (52 patients).1
 

Additional International Clinical Data

This evidence builds on our quadripolar standard of care, which has offered you more options to pace at the preferred LV site, resulting in:

  • Improved CRT outcome2,3
  • Fewer surgical revisions4
  • Reduced need for lead repositioning at implant, leading to shorter procedure times and decreased fluoroscopic exposure5,6
  • More basal pacing opportunities without compromising lead stability7,8



Quadra Assura MP CRT-P Advanced Features and Benefits

Now MRI Ready

The Quadra Assura MP CRT-D is MR conditional when used with specific leads and lead lengths, and allows full-body, 1.5T MRI scans that meet certain scan conditions.*

  • Meets industry-standard MRI testing requirements
  • Capable of full body 1.5T MRI imaging scans

Designed to Optimize Tissue Selection

The Quadra Assura MP CRT-D offers Auto VectSelect Quartet™ Test that:

  • Automatically identifies tissue sites with the latest activation via RV-LV conduction delays measurements
  • Performs threshold testing, assesses LVCap™ Confirm applicability and allows marking of PNS

Pacing at the tissue site of latest activation improves:

  • Acute hemodynamic response9
  • Reverse remodeling10
  • Quality of life10

Enhanced Programming Options
  • SyncAV™ CRT technology automatically adjusts pacing based on real-time changes in a patient's cardiac condition.
  • Antitachycardia pacing (ATP) while charging and prior to charging in the VF zone further extends the programming options for terminating tachyarrhythmias without a high-voltage shock.
  • SenseAbility™ feature provides flexibility to fine-tune programming around T-wave oversensing without decreasing sensitivity.

Additional Monitoring and Safety Features
  • ShockGuard™ technology with DecisionTx™ programming
  • SecureSense™ RV lead noise discrimination
  • Far Field MD™ morphology discrimination
  • DeFT Response™ technology
  • CorVue™ congestion monitoring feature
  • QuickOpt™ timing cycle optimization

Building Comprehensive Heart Failure Management

The Quadra Assura MP™ CRT-D is one of our heart failure management therapies. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about our approach to heart failure management.

Resources and Documentation

Model NameHeader ModelModel Number
Quadra AssuraDF-1/IS-1CD3371-40C

 

*See MRI Ready Systems Manual for device and lead combinations and associated MRI scan parameters.

References

  1. Niazi, I., Baker, J., Corbisiero, R., Love, C., Martin, D., Sheppard, R., ... Tomassoni, G., & MPP Investigators. (2017). Safety and efficacy of Multipoint pacing in cardiac resynchronization therapy: The MultiPoint pacing trial. JACC: Clinical Electrophysiology, 3 (13), 1510-1518. https://www.sciencedirect.com/science/article/pii/S2405500X17306084
  2. Forleo,. G. B., Mantica, M., Di Biase, L., Panattoni, G., Della Rocca, D. G., Papavasileiou, L. P., … Romeo, F. (2012). Clinical and procedural outcome of patients implanted with a quadripolar left ventricular lead: Early results of a prospective multicenter study. Heart Rhythm, 9(11), 1822-1828. https://www.heartrhythmjournal.com/article/S1547-5271(12)00767-9/fulltext
  3. Turakhia, M., Cao, M., Fischer, A., Arnold, E. M., Sloman, L. S., Dalal, N., & Gold, M. (2014, June). Reduced mortality with quadripolar compared to bipolar left ventricular leads in cardiac resynchronization therapy. Presented at the World Congress in Cardiac Electrophysiology and Cardiac Techniques, Nice, France. Retrospective analysis; not prespecified.
  4. Forleo, G. B., Della Rocca, D. G., Papavasileiou, L. P., Molfetta, A. D., Santini, L., & Romeo, F. (2011). Left ventricular pacing with a new quadripolar transvenous lead for CRT: Early results of a prospective comparison with conventional implant outcomes. Heart Rhythm, 8(1), 31-37. https://www.heartrhythmjournal.com/article/S1547-5271(10)01019-2/fulltext
  5. Dänschel, W., Sperzel, J. K., Gutleben, K., Kranig, W., Mortensen, P., Connelly, D., … Hallier, B. (2010). Initial clinical experience with a novel left ventricular quadripolar lead. Europace, 12(Suppl. 1), i127. https://academic.oup.com/europace/article/12/suppl_1/i13/492430
  6. Duray, G. Z., Hohnloser, S. H., Israel, C. W. (2008). Coronary sinus side branches for cardiac resynchronization therapy: prospective evaluation of availability, implant success, and procedural determinants. Journal of Cardiovascular Electrophysiology, 19(5), 489-494. https://onlinelibrary.wiley.com/doi/10.1111/j.1540-8167.2007.01096.x
  7. Merchant, F. M., Heist, E. K., McCarty, D., Kumar, P., Das, S., Blendea, D., … Singh, J. P. (2010). Impact of segmental left ventricular lead position on cardiac resynchronization therapy outcomes. Heart Rhythm, 7(5), 639-644. http://dx.doi.org/10.1016/j.htrhtm.2010.01.035
  8. Singh, J. P., Klein, H. U., Huang, D. T., Reek, S., Kuniss, M., Quesada, A., … Moss, A. J. (2011). Left ventricular lead position and clinical outcome in the Multicenter Automatic Defibrillator Implantation Trial Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation, 123(11), 1159-1166. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.110.000646
  9. Yu, Y., Auricchio, A., Butter, C., Stellbrink, C., Vogt, J., Goehring, A., & Spinelli, J. (2002). Assessment of resynchronization effectiveness of left ventricular lead site. Journal of Cardiac Failure, 8(4S), S72.
  10. Gold, M., Birgersdotter-Green, U., Singh J., Ellenbogen, K., Yu, Y., Meyer, T., …Tchou, P. (2011). The relationship between ventricular electrical delay and left ventricular remodeling with cardiac resynchronization therapy. European Heart Journal, 32(20), 2516-2524. https://academic.oup.com/eurheartj/article/32/20/2516/487679

MAT-2117060 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v13.0